Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300
The first patent, No. 9,809,623, covers methods of treating inflammatory bowel diseases (IBD) with PTG-100, an orally stable alpha-4-beta-7 integrin peptide inhibitor. PTG-100 was discovered using Protagonist's proprietary technology platform and is currently in Phase 2b testing in patients with moderate-to-severe, active ulcerative colitis. The new patent adds to previously granted U.S. patents No. 9,273,093 and 9,518,091, which also provide protection for the company's alpha-4-beta-7 integrin peptide inhibitors, including PTG-100.
The second patent, No. 9,822,157, covers peptide analogues of hepcidin, including PTG-300, and related pharmaceutical compositions. PTG-300, the company's lead peptide hepcidin mimetic, recently completed a Phase 1 clinical study in healthy volunteers. Protagonist plans to initiate Phase 2 trials of PTG-300 in patients with beta-thalassemia and myelodysplastic syndrome during 2018.
"These new patents further strengthen the long-term intellectual property protection for these clinical-stage assets, both of which have emerged from our innovative peptide technology platform," said
PTG-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global Phase 2B clinical trial for the treatment of moderate-to-severe ulcerative colitis. PTG-200, a potential first-in-class oral Interleukin-23 receptor antagonist in development for the treatment of IBD, initially Crohn's disease, is currently being studied in a Phase 1 clinical trial. Protagonist has entered into a worldwide agreement with
In addition to PTG-100 and PTG-200, the company is developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of anemia in iron overload disorders, including rare diseases such as beta-thalassemia and myelodysplastic syndromes. PTG-300 recently completed a Phase 1 clinical trial.
Protagonist is headquartered in
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our programs and our intellectual property. In some cases, you can identify these statements by forward-looking words such as "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to adequately protect our intellectual property. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our quarterly report on Form 10-Q for the quarter ended
Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Email: Joan@bioscribe.com; or For Investors, The Trout Group, Marcy Nanus, Tel: +1 646-378-2927, Email: email@example.com